Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Revolution Medicines, Inc.
RVMD
NASDAQ·Healthcare·Biotechnology·Mkt cap $39.9B
$189.24
▲ +0.92%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$34.00 - $193.10
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 404.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary RAS pathway inhibition platform targeting multiple frontier oncology targets
- Strategic partnership with Sanofi providing development expertise and commercialization support
- Differentiated pipeline with mutant-selective and hyperactivated inhibitor approaches
- Focus on RAS-addicted cancers with limited current treatment options
- Clinical-stage validation with multiple candidates in active development
Bear Case
1 risk
- Average volatility.
Growth
Revenue decline expected
Advancement of RMC-4630 through Phase 1/2 trials with potential for expanded indications
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+89.2% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying RVMD right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 5, 2026
MAY 6, 2026
Reported EPS of -$2.29 vs -$1.83 consensus (-25.1% surprise).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-25.1%
Next: May 5, 2026
Revenue trend · last 8Q
—
—
-100%
—
—
—
—
—
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
14 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$180.50
▼ -4.6% vs $189.24
Latest: Needham · $235.00 · Jun 29, 2026
8 analysts covering
vs Industry
How RVMD stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related